Navigation Links
Oncothyreon to receive milestone payment
Date:5/14/2008

uture prospects, this release contains statements that are forward looking, including statements related to payments Oncothyreon may expect to receive; the therapeutic and commercial potential of Stimuvax; future clinical development plans; the details of clinical trials; and the anticipated future size of the market for Stimuvax. These forward-looking statements represent Oncothyreon's intentions, plans, expectations and beliefs and are based on its management's experience and assessment of historical and future trends and the application of key assumptions relating to future events and circumstances.

Forward-looking statements involve risks and uncertainties, including risks and uncertainties related to Oncothyreon's business and the general economic environment. Many of these risks and uncertainties are beyond Oncothyreon's control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements. Risks, uncertainties, and assumptions include those predicting the timing, duration and results of clinical trials, the timing and results of regulatory reviews, the safety and efficacy of Stimuvax, and the possibility of future milestone and royalty payments. There can be no guarantee that the results of earlier trials will be predictive of either safety or efficacy in future trials. These and other risks and uncertainties are described in the reports and other documents filed by Oncothyreon Inc. with the SEC and/or Canadian regulatory authorities.

Although Oncothyreon believes that any forward-looking statements contained herein are reasonable, it can give no assurance that its expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of the risks and uncertainties associated with Oncothyreon, you are encouraged to review the official corporate documents filed by Oncothyreon I
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncothyreon Reports First Quarter 2008 Financial Results
2. Oncothyreon files investigational new drug application for PX-866 oncology compound
3. Data for Oncothyreons PX-12 and PX-866 presented at AACR Annual Meeting
4. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
5. Oncothyreon announces effectiveness of shelf registration statement
6. Oncothyreon announces issuance of patent for PX-867
7. Oncothyreon to present at upcoming investment conferences
8. Oncothyreon reports full year and fourth quarter 2007 financial results
9. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
10. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
11. Oncothyreon launches new corporate website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Best Sanitizers, Inc., the first company ... sanitizer, asks food processors and food handling professionals to ... they’re currently using to Best Sanitizers’ Alpet® E3 ... to fighting cross-contamination and the spread of pathogens in ... are key criteria that make a hand sanitizer most ...
(Date:8/28/2014)... converters are important devices in spintronics, an electronic ... of electrons but also on their spin and ... of electric into magnetic signals and vice versa. ... from the Institute of Physics at Johannes Gutenberg ... UK, Prague, and Japan, has for the first ...
(Date:8/28/2014)... month, executives from clinical trial marketing firm BBK Worldwide will ... Patient-Centered Clinical Trials 2014 , to be held at the ... 4-5. Patient recruitment experts Bonnie A. Brescia , ... insights on the benefits of employing an effective patient engagement ... to mobile apps – can be used to drive study ...
(Date:8/28/2014)... , Aug. 28, 2014  Armetheon, Inc. ... developing novel mid- to late-stage cardiovascular drug candidates, ... in its first round of financing. The Series ... and Hercules Bioventures with participation from investors that ... pharmaceutical executive, Dr. Larry Hsu , the ...
Breaking Biology Technology:Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3A new, tunable device for spintronics 2A new, tunable device for spintronics 3BBK Worldwide Leads Sessions at Key September Events 2Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3
... David H. Murdock Research Institute (DHMRI) today announced the ... a next step in the continued growth of the ... Kannapolis, NC. Driven by a mission to accelerate the ... of immune-related diseases, the DHMRI provides integrated, state-of-the-art genomic, ...
... energy-guru and favourite read of Bill Gates, Vaclav Smil,s gloomy ... Raynolds. "You need a hug," Raynolds said. ... took place on TVO,s The Agenda with Steve Paikan live ... is now archived at http://wgsi.org/events/tvos-agenda-steve-paikin-1 . THE ...
... June 8, 2011 Northwest Biotherapeutics (OTC.BB: NWBO) today ... its management team, adding several highly experienced executives.  Ms. ... Board since May 2007, has been appointed Chief Executive ... in the field of cancer immune therapies, is joining ...
Cached Biology Technology:David H. Murdock Research Institute Assumes Control of the Immune Tolerance Institute and Establishes a State of the Art Human Immune Monitoring Laboratory for Biomarker Discovery and Development 2David H. Murdock Research Institute Assumes Control of the Immune Tolerance Institute and Establishes a State of the Art Human Immune Monitoring Laboratory for Biomarker Discovery and Development 3High voltage! Power experts pull out all the stops at international energy meeting 2Northwest Biotherapeutics Announces Change and Expansion of Management Team 2Northwest Biotherapeutics Announces Change and Expansion of Management Team 3Northwest Biotherapeutics Announces Change and Expansion of Management Team 4Northwest Biotherapeutics Announces Change and Expansion of Management Team 5Northwest Biotherapeutics Announces Change and Expansion of Management Team 6
(Date:8/28/2014)... Energy production systems are good examples of complex ... like a networkincluding water for cooling, transport to ... management. Every step in the network chain is ... all mutually dependent. A team of UK-based scientists ... previously explored. The findings have been published in ...
(Date:8/28/2014)... 28, 2014 Dyslexia, the most commonly diagnosed ... neurological reading disability that occurs when the regions ... function normally. , The use of non-invasive functional ... is disrupted in dyslexia. However, most prior work ... brain regions, leaving a gap in our understanding ...
(Date:8/28/2014)... This news release is available in German . ... electronic products are now built with the help of sophisticated ... are fixed, are an important part of these assembly lines. ... are attached in various work stages arranged in a precise ... the end of the line. , The creation of such ...
Breaking Biology News(10 mins):Inter-dependent networks stress test 2Dyslexic readers have disrupted network connections in the brain 2Nanoscale assembly line 2Nanoscale assembly line 3
... and neck cancer in the United States this year and ... published this week in the journal Carcinogenesis shows ... extract (GSE) kills head and neck squamous cell carcinoma cells, ... effect," says Rajesh Agarwal, PhD, investigator at the University of ...
... Cancer is one of the most common causes of ... radiotherapy, chemotherapy, and targeting therapies, which are intended to ... fail, resulting in tumor metastasis and recurrence. Therefore, there ... recent years, an increasing number of studies have revealed ...
... Cell Press reinforces its commitment to provide a broad ... the inaugural issue of a new open-access journal: Cell ... months of hard work on the part of our authors, ... editorial and production teams, the first issue is available online ...
Cached Biology News:Immunological mechanisms of oncolytic adenoviral therapy 2Immunological mechanisms of oncolytic adenoviral therapy 3Cell Press launches a new open-access journal, Cell Reports 2
... microarray data using Asuragens bioinformatics expertise. We ... to extensive data analysis using the most ... in combination with the Gene Expression Profiling ... ,Normalization and basic statistical analysis including publication ...
... This CLS number is a ... easily match Cornings product number. ... please order under the old ... customer service for assistance. ...
... Maximize the value of your microarray ... the support you need from consultation to ... to date methods. Utilize our expertise in ... or from your own microarray experiments., ,Normalization ...
BD Falcon 850 cm Smooth-surface TufRol Roller Bottle, tissue-culture treated polystyrene, blow-molded one-piece design, with easy on/off non-vented cap. (2/sp, 20/ca) Packaging: 2 / pack, 20 /...
Biology Products: